TradingKey

Mais detalhes de Alkermes Plc Empresa

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Informações da empresa

Código da empresaALKS

Nome da EmpresaAlkermes Plc

Data de listagemJul 16, 1991

CEOMr. Richard F. Pops

Número de funcionários1800

Tipo de títulosOrdinary Share

Fim do ano fiscalJul 16

EndereçoConnaught House

CidadeDUBLIN

Bolsa de valoresNASDAQ Global Select Consolidated

PaísIreland

Código postalD04 C5Y6

Telefone35317728000

Sitehttps://www.alkermes.com/

Código da empresaALKS

Data de listagemJul 16, 1991

CEOMr. Richard F. Pops

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

204.25K

--

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

77.74K

--

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+26.46%

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

+12.23%

Ms. Nancy S. Lurker

Independent Director

10.71K

+131.91%

Dr. Nancy L. Snyderman, M.D.

Independent Director

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

--

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

204.25K

--

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

77.74K

--

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Detalhamento da receita

Moeda: USDAtualizado em: dom, 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

VIVITROL

101.00M

32.95%

ARISTADA

73.47M

23.97%

LYBALVI

70.02M

22.84%

Royalty Revenue - VUMERITY

21.86M

7.13%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

17.75M

5.79%

Other

22.41M

7.31%

Sem dados

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

VIVITROL

101.00M

32.95%

ARISTADA

73.47M

23.97%

LYBALVI

70.02M

22.84%

Royalty Revenue - VUMERITY

21.86M

7.13%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

17.75M

5.79%

Other

22.41M

7.31%

Distribuição de ações

Atualizado em: sáb, 17 de mai

Investidores

Tipos de investidores

Investidores

Proporção

BlackRock Institutional Trust Company, N.A.

14.53%

The Vanguard Group, Inc.

11.00%

T. Rowe Price Associates, Inc.

7.04%

State Street Global Advisors (US)

4.86%

RTW Investments L.P.

4.17%

Other

58.40%

Investidores

Proporção

BlackRock Institutional Trust Company, N.A.

14.53%

The Vanguard Group, Inc.

11.00%

T. Rowe Price Associates, Inc.

7.04%

State Street Global Advisors (US)

4.86%

RTW Investments L.P.

4.17%

Other

58.40%

Tipos de investidores

Investidores

Proporção

Investment Advisor

57.22%

Investment Advisor/Hedge Fund

30.61%

Hedge Fund

12.64%

Research Firm

2.77%

Individual Investor

1.66%

Pension Fund

1.62%

Sovereign Wealth Fund

1.24%

Bank and Trust

0.42%

Private Equity

0.36%

Participação acionária institucional

Atualizado em: ter, 1 de jul

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q2

769

179.19M

108.55%

-26.81M

2025Q1

781

180.42M

109.41%

-27.12M

2024Q4

750

175.04M

107.61%

-39.68M

2024Q3

727

186.93M

115.42%

-33.14M

2024Q2

708

187.79M

113.20%

-24.77M

2024Q1

682

184.21M

108.96%

-28.40M

2023Q4

653

184.12M

110.36%

-5.13M

2023Q3

620

171.53M

102.92%

-4.71M

2023Q2

610

167.10M

100.38%

-17.86M

2023Q1

604

167.47M

100.88%

-20.36M

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

BlackRock Institutional Trust Company, N.A.

23.98M

14.54%

-541.92K

-2.21%

Mar 31, 2025

The Vanguard Group, Inc.

18.16M

11.01%

-283.51K

-1.54%

Mar 31, 2025

T. Rowe Price Associates, Inc.

11.62M

7.05%

-472.94K

-3.91%

Mar 31, 2025

State Street Global Advisors (US)

8.02M

4.87%

-792.30K

-8.99%

Mar 31, 2025

RTW Investments L.P.

6.88M

4.17%

-673.14K

-8.91%

Mar 31, 2025

Renaissance Technologies LLC

5.74M

3.48%

+260.10K

+4.75%

Mar 31, 2025

Baker Bros. Advisors LP

4.48M

2.72%

+301.53K

+7.21%

Mar 31, 2025

JP Morgan Asset Management

4.13M

2.5%

+3.88M

+1560.15%

Mar 31, 2025

Geode Capital Management, L.L.C.

3.94M

2.39%

+121.05K

+3.17%

Mar 31, 2025

American Century Investment Management, Inc.

3.47M

2.1%

+14.97K

+0.43%

Mar 31, 2025

Ver Mais

ETFs Relacionados

Atualizado em: sáb, 2 de ago

Nome

Proporção

AdvisorShares Psychedelics ETF

6.14%

iShares Neuroscience and Healthcare ETF

3.95%

Invesco S&P SmallCap Health Care ETF

3.37%

First Trust NYSE Arca Biotechnology Index Fund

3.33%

ALPS Medical Breakthroughs ETF

3.19%

Tema Neuroscience and Mental Health ETF

1.88%

Knowledge Leaders Developed World ETF

1.68%

Pacer US Small Cap Cash Cows Growth Leaders ETF

1.4%

Invesco S&P SmallCap Quality ETF

1.34%

Janus Henderson Small Cap Growth Alpha ETF

1.25%

Ver Mais

AdvisorShares Psychedelics ETF

Proporção6.14%

iShares Neuroscience and Healthcare ETF

Proporção3.95%

Invesco S&P SmallCap Health Care ETF

Proporção3.37%

First Trust NYSE Arca Biotechnology Index Fund

Proporção3.33%

ALPS Medical Breakthroughs ETF

Proporção3.19%

Tema Neuroscience and Mental Health ETF

Proporção1.88%

Knowledge Leaders Developed World ETF

Proporção1.68%

Pacer US Small Cap Cash Cows Growth Leaders ETF

Proporção1.4%

Invesco S&P SmallCap Quality ETF

Proporção1.34%

Janus Henderson Small Cap Growth Alpha ETF

Proporção1.25%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

Alkermes Plc

26.510USD

Alkermes Plc

26.510

Visão Geral

Empresa

Serviços Financeiros